TW202311254A - 血紅素之調節劑之固態形式 - Google Patents
血紅素之調節劑之固態形式 Download PDFInfo
- Publication number
- TW202311254A TW202311254A TW111118076A TW111118076A TW202311254A TW 202311254 A TW202311254 A TW 202311254A TW 111118076 A TW111118076 A TW 111118076A TW 111118076 A TW111118076 A TW 111118076A TW 202311254 A TW202311254 A TW 202311254A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- crystalline
- salt form
- salt
- diffraction pattern
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188833P | 2021-05-14 | 2021-05-14 | |
| US63/188,833 | 2021-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202311254A true TW202311254A (zh) | 2023-03-16 |
Family
ID=82020064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111118076A TW202311254A (zh) | 2021-05-14 | 2022-05-13 | 血紅素之調節劑之固態形式 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11851424B2 (https=) |
| EP (1) | EP4337659A1 (https=) |
| JP (1) | JP2024520897A (https=) |
| KR (1) | KR20240008356A (https=) |
| CN (1) | CN117337285A (https=) |
| AR (1) | AR126649A1 (https=) |
| AU (1) | AU2022273787B2 (https=) |
| BR (1) | BR112023021606A2 (https=) |
| CA (1) | CA3219786A1 (https=) |
| MX (1) | MX2023012156A (https=) |
| TW (1) | TW202311254A (https=) |
| WO (1) | WO2022241278A1 (https=) |
| ZA (1) | ZA202309517B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250041312A1 (en) * | 2021-12-10 | 2025-02-06 | Global Blood Therapeutics, Inc. | Methods of administering a modulator of hemoglobin |
| TW202515579A (zh) * | 2023-06-13 | 2025-04-16 | 美商全球血液治療公司 | 投予血紅素的調節劑之方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4432987A (en) * | 1982-04-23 | 1984-02-21 | Pfizer Inc. | Crystalline benzenesulfonate salts of sultamicillin |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| SG10201802911RA (en) * | 2013-03-15 | 2018-05-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| HRP20220295T1 (hr) | 2018-11-19 | 2022-05-13 | Global Blood Therapeutics, Inc. | Spojevi 2-formil-3-hidroksifeniloksimetila koji mogu modulirati hemoglobin |
| WO2022241286A1 (en) * | 2021-05-14 | 2022-11-17 | Global Blood Therapeutics, Inc. | Methods of making a modulator of hemoglobin |
-
2022
- 2022-05-13 CA CA3219786A patent/CA3219786A1/en active Pending
- 2022-05-13 CN CN202280035091.5A patent/CN117337285A/zh active Pending
- 2022-05-13 EP EP22729906.2A patent/EP4337659A1/en active Pending
- 2022-05-13 JP JP2023569774A patent/JP2024520897A/ja active Pending
- 2022-05-13 KR KR1020237043235A patent/KR20240008356A/ko active Pending
- 2022-05-13 MX MX2023012156A patent/MX2023012156A/es unknown
- 2022-05-13 AU AU2022273787A patent/AU2022273787B2/en active Active
- 2022-05-13 WO PCT/US2022/029289 patent/WO2022241278A1/en not_active Ceased
- 2022-05-13 AR ARP220101301A patent/AR126649A1/es not_active Application Discontinuation
- 2022-05-13 TW TW111118076A patent/TW202311254A/zh unknown
- 2022-05-13 BR BR112023021606A patent/BR112023021606A2/pt unknown
- 2022-05-13 US US17/744,537 patent/US11851424B2/en active Active
-
2023
- 2023-10-11 ZA ZA2023/09517A patent/ZA202309517B/en unknown
- 2023-11-01 US US18/499,491 patent/US12473277B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023012156A (es) | 2023-10-26 |
| BR112023021606A2 (pt) | 2023-12-19 |
| CN117337285A (zh) | 2024-01-02 |
| ZA202309517B (en) | 2024-06-26 |
| EP4337659A1 (en) | 2024-03-20 |
| US20220363674A1 (en) | 2022-11-17 |
| US11851424B2 (en) | 2023-12-26 |
| AR126649A1 (es) | 2023-11-01 |
| US12473277B2 (en) | 2025-11-18 |
| AU2022273787B2 (en) | 2025-04-03 |
| JP2024520897A (ja) | 2024-05-27 |
| AU2022273787A1 (en) | 2023-10-26 |
| US20240076290A1 (en) | 2024-03-07 |
| CA3219786A1 (en) | 2022-11-17 |
| KR20240008356A (ko) | 2024-01-18 |
| WO2022241278A1 (en) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2750676T5 (en) | Crystalline dihydrochloride hydrate salt of omecamtiv mecarbil and process for its preparation | |
| TWI588145B (zh) | 降伊波加因鹽非溶劑化物 | |
| US12473277B2 (en) | Solid forms of a modulator of hemoglobin | |
| TWI703143B (zh) | ４-（４-（１-異丙基-７-側氧基-１，４，６，７－四氫螺〔吲唑-５，４’-哌啶〕-１’-羰基）-６-甲氧基吡啶-２-基）苯甲酸之晶型 | |
| CN112020506B (zh) | 新生霉素类似物与脯氨酸的共晶体形式 | |
| CN119998282A (zh) | 固体形式和使用方法 | |
| HK40101540A (zh) | 血红蛋白之调节剂的固体形式 | |
| EP3853200B1 (en) | Erbumine salt of treprostinil | |
| AU2015392050B2 (en) | Fumarate of pyridylamine compound and crystals thereof | |
| WO2021001457A1 (en) | Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts | |
| EP4660195A1 (en) | Crystalline forms of avatrombopag maleate and preparation thereof | |
| US20250304635A1 (en) | Birinapant polymorph h | |
| HK40119275A (zh) | 新生霉素类似物与脯氨酸的共晶体形式 | |
| US10689387B2 (en) | Crystalline form of (1R,2R)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]-N-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazin-3-yl)cyclohexanecarboxamide | |
| CN117396460A (zh) | (r)-奥昔布宁d-苹果酸盐的固体形式 | |
| EA043230B1 (ru) | Эрбуминовая соль трепростинила | |
| HK1187046B (en) | Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate | |
| HK1187046A (en) | Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate | |
| NZ620948B2 (en) | Noribogaine salt ansolvates |